Sirtex SIR-spheres fail to meet primary endpoint in head-to-head trial
Sirtex Medical (ASX:SRX) shares are down slightly today after its radioactive microspheres failed to meet the primary endpoint in a liver cancer trial.
The company’s SIR-Spheres Y-90 resin microspheres did not improve survival in patients with advanced hepatocellular carcinoma compared to a group treated with the current standard of care, sorafenib.
Get the full story at our sister site, Drug Delivery Business News.
The post Sirtex SIR-spheres fail to meet primary endpoint in head-to-head trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Wall Street Beat Sirtex Medical Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Hepatocellular Carcinoma | Liver | Liver Cancer | Urology & Nephrology